3Lotta LA,Garagiola I,Palla R,et al.ADAMTS13mutations and polymor-phisms in congenital thrombotic thrombocytopenic purpura,Hum Mutat,2010,31(1):11-19.
4Shelat SG,Ai J,Zheng XL.Molecular biology of ADAMTS13anddiagnostic utility of ADAMTS13proteolytic activity and inhibitor as-says.Semin Thromb Hemost,2005,31(6):659-672.
5Jin SY,Skipwith CG.,Zheng XL.Amino acid residues Arg659,Arg660and Tyr661in the ADAMTS13spacer domain are critical for recognition of von Willebrand factor.Blood,2010,115(11):2300-2310.
6Ferrari S,Mudde GC,Rieger M,etal.IgG subclass distribution of anti-ADAMTS13antibodies in patients with acquired thrombotic thrombocytopenic purpura,J Thromb Haemost.2009,7(10):1703-1710.
7Zheng XL,Wu HM,Shang D,et al.Multiple domains of ADAMTS13are targeted by autoantibodies against ADAMTS13in patients with acquired idiopa thic thrombotic thrombocytopenic pur-pura.Haematologica,2010,95(9):1555-1562.
8Coppo P,Busson M,Veyradier A,et al.HLA-DRB1*11:a strong risk factor for acquired severe ADAMTS13deficiency-related idio-pathic thrombotic throm-bocytopenic purpura in Caucasians.J Thromb Haemost,2010,8(4):856-859.
9Scully M,Brown J,Patel R,et al.Human leukocyte antigen associ-ation in idiopa thic thrombotic thrombocytopenic purpura:evidence for an immunogenetic link.,J Thromb Haemost.2010,8(2):257-262.
10George JN.How I treat patients with thrombotic thrombocy-topenic purpura-hemolytic uremic syndrome.Blood,2000,96(4):1223-1229.
